| <P style="BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0cm 0cm 0pt; WORD-SPACING: 0px; FONT: 14px/21px simsun; TEXT-TRANSFORM: none; COLOR: rgb(85,85,85); WORD-BREAK: normal; TEXT-INDENT: 24pt; PADDING-TOP: 0px; WHITE-SPACE: normal; LIST-STYLE-TYPE: none; LETTER-SPACING: normal; BACKGROUND-COLOR: white; TEXT-ALIGN: left; BORDER-RIGHT-WIDTH: 0px; WORD-WRAP: normal; orphans: 2; widows: 2; webkit-text-size-adjust: auto; webkit-text-stroke-width: 0px; border-image: initial; background-origin: initial; background-clip: initial" align=left><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">据</SPAN><FONT size=3><SPAN class=Apple-converted-space><FONT color=#555555> </FONT></SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">11</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">月</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">2</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">日</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">FierceBiotech</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">报道：近年问世的新血液稀化剂卓越的效果举世触目，它们的极强的抗凝作用引起的重大的安全问题阻碍了它们的开发进程。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">制药公司对付在服用这类药物时少数患者出现的严重出血问题的项目已经获得制药巨头辉瑞公司和百时美施贵宝的积极支持对。</SPAN></FONT><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US"><BR><SPAN style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal"><FONT style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal" face=Arial><FONT size=3> <WBR> <WBR> <WBR></FONT></FONT></SPAN></SPAN><FONT size=3><SPAN class=Apple-converted-space><FONT color=#555555> </FONT></SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">坐落于南旧金山的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">公司预计今年年底开始这项研究。该公司的蛋白质药物</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">PRT4445</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">可能逆转口服</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Xa</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">因子抑制剂，如辉瑞公司和百时美施贵宝的潜在重磅炸弹产品</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">（</SPAN><SPAN lang=EN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN">apixaban</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">，阿哌沙班）的活性。这项研究将以</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">PRT4445</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">作为</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">以及类似药物，如</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">公司的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">betrixaban</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">的解药。在达成的协议中规定</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">公司保留</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">PRT4445</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">开发和商业化的所有权利。</SPAN></FONT><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US"><BR><SPAN style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal"><FONT style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal" face=Arial><FONT size=3> <WBR> <WBR> <WBR></FONT></FONT></SPAN></SPAN><FONT size=3><SPAN class=Apple-converted-space><FONT color=#555555> </FONT></SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">在</SPAN></FONT><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">的临床开发中患者的安全一直备受关注，包括努力寻找在临床情况紧急（严重出血）情况下可供使用的解药，两家公司一直在为此努力。日后它们将与</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">公司合作，推进对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Portola</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">作为</SPAN><SPAN lang=EN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">潜在解药的研究。</SPAN></P>
<P style="BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0cm 0cm 0pt; WORD-SPACING: 0px; FONT: 14px/21px simsun; TEXT-TRANSFORM: none; COLOR: rgb(85,85,85); WORD-BREAK: normal; TEXT-INDENT: 0px; PADDING-TOP: 0px; WHITE-SPACE: normal; LIST-STYLE-TYPE: none; LETTER-SPACING: normal; BACKGROUND-COLOR: white; TEXT-ALIGN: left; BORDER-RIGHT-WIDTH: 0px; WORD-WRAP: normal; orphans: 2; widows: 2; webkit-text-size-adjust: auto; webkit-text-stroke-width: 0px; border-image: initial; background-origin: initial; background-clip: initial" align=left><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">出血风险使药品监管机构在审议</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">和谋求数十亿美元的市场的其它新一代血液稀化剂时举步不前。迄今没有如何解药可以处置这类血液稀化剂，包括辉瑞和百时美施贵宝的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">严重出血。这项合作研究协议的签订恰在</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">FDA</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">即将审批</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">用于房颤患者中风预防之际。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US"><BR><FONT style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal"><FONT face=Arial><FONT size=3><SPAN style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal"> <WBR> <WBR> <WBR></SPAN><SPAN class=Apple-converted-space> </SPAN>FDA</FONT></FONT></FONT></SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">计划于</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">2013</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">年</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">3</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">月</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">17</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">日</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">对上述申请作出决定。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">FDA</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN-US">Eliquis</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">及其竞争产品，即拜耳公司和强生公司的</SPAN><SPAN lang=EN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN"><A style="COLOR: rgb(100,129,76); TEXT-DECORATION: none" href="http://www.fiercebiotech.com/tags/xarelto"><SPAN style="COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; TEXT-DECORATION: none; WORD-WRAP: normal"><FONT style="WORD-BREAK: normal; LINE-HEIGHT: 24px; WORD-WRAP: normal" face=Arial size=3>Xarelto</FONT></SPAN></A></SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">（</SPAN><SPAN lang=EN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: Arial; WORD-WRAP: normal" xml:lang="EN">rivaroxaban</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">，</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; WORD-BREAK: normal; LINE-HEIGHT: 24px; FONT-FAMILY: 宋体; WORD-WRAP: normal">利伐沙班。口服片剂。国内注册名：拜瑞妥）的风险始终十分关注。</SPAN></P> |
